MSW MANAGEMENT -Multidisciplinary, Scientific Work and Management Journal
ISSN: 1053-7899
Vol. 36 Issue 2, 2026, Pages 1406-1408

5 FU LOADED LIPOSOMES FOR CANCER TREATMENT

Swetha. K[1], Dr. Bhargavi[2]
[1]Undergraduate Resident, Department of Oral Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai-600077
152001023.sdc@saveetha.com
[2]Department of Oral Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai-600077, Tamil Nadu, India
bargavip.sdc@saveetha.com

ABSTRACT:
Cancer remains a formidable challenge in modern medicine, necessitating innovative and targeted therapeutic approaches to improve outcomes for patients. Among the myriad strategies employed, 5-Fluorouracil (5-FU) has emerged as a potent chemotherapeutic agent due to its ability to disrupt DNA synthesis and inhibit cell proliferation. However, the clinical utility of 5-FU is limited by its non-specific distribution, rapid clearance, and dose-dependent toxicities.In response to these challenges, researchers have explored nanotechnology-based drug delivery systems as a promising avenue to enhance the therapeutic efficacy of 5-FU while minimizing its adverse effects.In active loading, drug internalization into preformed liposomes is typically driven by a transmembrane pH gradient. The pH outside the liposome allows some of the drug to exist in a unionized form, able to migrate across the lipid bilayer. 5 mg of 5Fu is loaded in lipid bilayer and stirred for 4 hours.5-fluorouracil (5-FU) is a chemotherapeutical agent used to treat cancers including breast and colorectal. Working as an antimetabolite to prevent cancer cell proliferation, it primarily inhibits the enzyme thymidylate synthase blocking the thymidine formation required for DNA synthesis. Liposomes are widely used as carriers for anticancer drugs due to their ability to prolong the retention of encapsulated drugs in blood plasma while directing their distribution increasingly into tumor tissue. In conclusion, 5-FU loaded liposomes hold significant promise in revolutionising cancer treatment. Their potential to improve drug delivery, minimize side effects, and enable personalized therapeutic strategies underscores the importance of continued research and development in this field. However, addressing challenges and ensuring the safety and efficacy of these formulations are critical steps towards their successful clinical implementation.
Keywords : neglected disease, diarrhea, cholera,medicine.

1. INTRODUCTION:

Cancer remains a formidable challenge in modern medicine, necessitating innovative and targeted therapeutic approaches to improve outcomes for patients(1). Among the myriad strategies employed, 5-Fluorouracil (5-FU)(2) has emerged as a potent chemotherapeutic agent due to its ability to disrupt DNA synthesis and inhibit cell proliferation. However, the clinical utility of 5-FU is limited by its non-specific distribution, rapid clearance, and dose-dependent toxicities.In response to these challenges, researchers have explored nanotechnology-based drug delivery systems as a promising avenue to enhance the therapeutic efficacy of 5-FU while minimizing its adverse effects. Among these nanocarriers, liposomes have gained considerable attention for their ability to encapsulate and deliver drugs selectively to target tissues(1,3).Liposomes are lipid-based vesicles with a unique structure that allows for the encapsulation of hydrophilic and hydrophobic drugs within their aqueous core or lipid bilayer, respectively. This versatility makes liposomes an ideal candidate for improving the pharmacokinetics and bioavailability of 5-FU.When 5-FU is encapsulated within liposomes, several advantages are realized. Firstly, liposomal formulations protect the drug from degradation,(4) extending its circulation time and enhancing its accumulation at the tumor site through the enhanced permeability and retention (EPR) effect. Secondly, the controlled release of 5-FU from liposomes allows for sustained drug delivery, reducing the frequency of administration and minimizing systemic toxicity(5). Additionally, the encapsulation of 5-FU within liposomes enables the possibility of combination therapies, allowing for the co-delivery of multiple drugs to enhance(6) synergistic effects.This introduction sets the stage for a comprehensive exploration of the potential of 5-FU-loaded liposomes as a novel and promising strategy in cancer treatment(5,7). By harnessing the benefits of nanotechnology, these formulations aim to overcome the limitations of conventional 5-FU therapy, offering a more targeted and effective approach to combatting cancer while(8) minimizing the impact on healthy tissues. In the subsequent discussion, we will delve into the key attributes, mechanisms of action, and preclinical/clinical findings associated with 5-FU-loaded liposomes, shedding light on their potential to revolutionize cancer therapeutics.Cancer, an intricate and formidable adversary to human health, continues to pose significant challenges to both patients and the medical community(9). The relentless pursuit of effective treatment strategies has led to a dynamic landscape of innovation and discovery, marking a new era in the fight against this complex group of diseases.In recent years, groundbreaking advancements in cancer treatment have emerged, reshaping the way we approach and manage various malignancies. This article endeavors to provide a comprehensive overview of the latest and most promising innovations in cancer treatment, offering insights into novel therapeutic modalities, targeted interventions, and the convergence of cutting-edge technologies(10).The contemporary treatment paradigm emphasizes precision medicine, recognizing the inherent heterogeneity of cancer and tailoring interventions to individual patients. From immunotherapies that harness the body's immune system to targeted therapies designed to disrupt specific molecular pathways, the arsenal against cancer is expanding rapidly(11). This article aims to unravel the intricacies of these innovative approaches, shedding light on their mechanisms, efficacy, and potential impact on patient outcomes.

Furthermore, we will explore the role of emerging technologies such as artificial intelligence, genomics, and nanotechnology in revolutionizing cancer diagnosis, prognosis, and treatment planning(12). The integration of these technologies into the clinical setting holds the promise of more accurate and personalized therapeutic strategies, ultimately improving the effectiveness of cancer care.As we embark on this exploration of the frontiers of cancer treatment, it is imperative to consider the holistic nature of cancer care(13). Beyond molecular and technological advancements,(14) the article will also delve into the evolving landscape of supportive care, patient-centered approaches, and the importance of multidisciplinary collaboration in ensuring comprehensive and compassionate cancer treatment.

2. MATERIALS AND METHODS:

In active loading, drug internalization into preformed liposomes is typically driven by a transmembrane pH gradient. The pH outside the liposome allows some of the drug to exist in a unionized form, able to migrate across the lipid bilayer. 5 mg of 5Fu is loaded in lipid bilayer and stirred for 4 hours.
5-fluorouracil (5-FU) is a chemotherapeutical agent used to treat cancers including breast and colorectal. Working as an antimetabolite to prevent cancer cell proliferation, it primarily inhibits the enzyme thymidylate synthase blocking the thymidine formation required for DNA synthesis.
Liposomes are widely used as carriers for anticancer drugs due to their ability to prolong the retention of encapsulated drugs in blood plasma while directing their distribution increasingly into tumor tissue

3. RESULTS:

3.1 FIGURE 1 : HIGH MAGNIFICATION SEM ANALYSIS



Figure 1 shows that The SEM image of 5-FU loaded liposomes shows irregular spherical vesicles with rough and porous surface morphology. The particles appear aggregated with distinct vesicular boundaries, confirming successful liposome formation and drug encapsulation. The nanoscale porous structure may enhance drug loading and controlled release of 5-fluorouracil. Overall, the SEM analysis supports the potential of 5-FU loaded liposomes as an effective nano-drug delivery system for anticancer therapy.

3.2 FIGURE 2 : LOW MAGNIFICATION SEM ANALYSIS

MSW MANAGEMENT -Multidisciplinary, Scientific Work and Management Journal
ISSN: 1053-7899
Vol. 36 Issue 2, 2026, Pages 1406-1408



Figure 2 shows that The SEM image of 5-FU loaded liposomes at ×7.00k magnification shows irregularly shaped, aggregated vesicular particles with a rough and porous surface morphology. The presence of interconnected porous networks and distinct vesicular structures indicates successful liposome formation and effective encapsulation of 5-fluorouracil. The particles appear in the nano-to-submicron range with slight agglomeration, which may be due to particle interaction during formulation. The porous surface characteristics may contribute to enhanced drug loading and sustained drug release. Overall, the SEM analysis confirms the successful preparation of 5-FU loaded liposomes suitable for targeted anticancer drug delivery applications.

3.3 SEM morphology spherical morphology,uniform size and 10 to 20 nm



3.4 Anti cancer activity



FTIR to identify the functional group analysis

4. DISCUSSION :

5-fluorouracil (5-FU) is a chemotherapeutical agent used to treat cancers including breast and colorectal. Working as an antimetabolite to prevent cancer cell proliferation, it primarily inhibits the enzyme thymidylate synthase blocking the thymidine formation required for DNA synthesis(15). Liposomes are widely used as carriers for anticancer drugs due to their ability to prolong the retention of encapsulated drugs in blood plasma while directing their distribution increasingly into tumor tissue. The main aim of the present study was to assess the impact of the different liposomal formulations (including neutral and cationic PEGylated liposomes) on the exposure of 5-fluorouracil (5-FU) to tumor tissue relative to healthy tissue. 5-FU is a highly permeable compound, polymer complexes were formed through electrostatic interactions with ternary copper and polyethyleneimine (PEI) to retard premature drug release from the liposomal formulations and thus, enhance tumor exposure to the drug.The discussion of 5-Fluorouracil (5-FU) loaded liposomes for cancer treatment involves a thorough analysis of the potential benefits, challenges, and implications of this innovative drug delivery system(16). A comparative analysis of studies investigating 5-FU loaded liposomes

MSW MANAGEMENT -Multidisciplinary, Scientific Work and Management Journal
ISSN: 1053-7899
Vol. 36 Issue 2, 2026, Pages 1406-1408

alongside conventional 5-FU treatments or other drug delivery systems.Understanding how 5-FU loaded liposomes perform in relation to other modalities provides insights into their relative efficacy, helping clinicians and researchers make informed decisions about treatment options.Exploring studies that investigate the synergistic effects of combining 5-FU loaded liposomes with other anticancer agents(17).Assessing the potential synergies provides a comprehensive view of how liposomal formulations fit into the landscape of combination therapies, potentially addressing the challenges of drug resistance and improving overall treatment outcomes.Examining literature on patient stratification based on tumor characteristics and molecular profiling, particularly in the context of 5-FU loaded liposomes.Understanding how patient-specific factors influence treatment response allows for a more personalized approach, potentially improving the precision and effectiveness of 5-FU loaded liposomes in diverse patient populations(18).Long-Term Analyzing studies that delve into the long-term safety profile of 5-FU loaded liposomes, considering potential adverse effects and systemic toxicity.Addressing safety concerns is critical for the clinical translation of liposomal formulations. Comparative assessments with other delivery systems contribute to a comprehensive evaluation of the risk-benefit profile.In vivo Studies and Clinical Trials.Reviewing in vivo studies and clinical trials involving 5-FU loaded liposomes, considering factors such as patient outcomes, survival rates, and quality of life(19).Evaluating the real-world impact of 5-FU loaded liposomes in clinical settings provides valuable insights into their feasibility, tolerability, and effectiveness, guiding future research and clinical practice.Technological Advances in Liposomal Formulations: Exploring recent technological innovations in liposomal formulations beyond 5-FU, considering advancements in liposomal design, drug loading techniques, and targeting strategies.Understanding the broader landscape of liposomal research helps contextualize the specific contributions and challenges associated with 5-FU loaded liposomes, fostering a deeper appreciation for the evolving field(19,20).Investigating studies that conduct cost-benefit analyses comparing 5-FU loaded liposomes with other treatment modalities, taking into account factors such as manufacturing costs, treatment efficacy, and healthcare resource utilization.Economic considerations are crucial for the practical implementation of novel therapies. A comprehensive analysis of cost-effectiveness contributes to the decision-making process for clinicians, policymakers, and healthcare providers.

5. CONCLUSION:

In conclusion, 5-FU loaded liposomes hold significant promise in revolutionizing cancer treatment. Their potential to improve drug delivery, minimize side effects, and enable personalized therapeutic strategies underscores the importance of continued research and development in this field. However, addressing challenges and ensuring the safety and efficacy of these formulations are critical steps 6. towards their successful clinical implementation.

SOURCE OF FUNDING:

The present study was supported by the following agencies

- Saveetha Institute of Medical and Technical Science,
- Saveetha Dental College and Hospitals,
- Saveetha University

- **CONFLICT OF INTEREST**

The authors reported the conflict of interest while performing this study to be nil

- **ACKNOWLEDGEMENT SKULL MEASUREMENT**

We acknowledge and thank all the participants for their cooperation in the study

6. REFERENCES:

1. Azarifar Z, Amini R, Tanzadehpanah H, Afshar S, Najafi R. In vitro co-delivery of 5-fluorouracil and all-trans retinoic acid by PEGylated liposomes for colorectal cancer treatment. Mol Biol Rep [Internet]. 2023 Oct 30; Available from: http://dx.doi.org/10.1007/s11033-023-08888-2
2. Website [Internet]. Available from: https://www.researchgate.net/publication/357409572_Knowledge_and_Awareness_about_Postpartum_Distress_among_the_Students_of_Saveetha_Dental_College
3. Oliveira JV, Almeida GC, Nogueira MCBL, Aguiar Júnior FCA, Melo AO, Silva TDS, et al. 4-amino-2-phenyl-6-(p-fluorophenyl)-5-carbonitrile-pyrimidine-bis-substituted-loaded liposomes as promising system for cancer treatment. An Acad Bras Cienc. 2023 Jul 10;95(suppl 1):e20211078.
4. Ann Preethy N, Somasundaram S. Safety and physiologic effects of intranasal midazolam and nitrous oxide inhalation based sedation in children visiting Saveetha Dental College and Hospitals, India. Bioinformation. 2022 Jan 31;18(1):26–35.
5. Chen T, Chen H, Jiang Y, Yan Q, Zheng S, Wu M. Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment. Pharmaceuticals [Internet]. 2022 Jul 17;15(7). Available from: http://dx.doi.org/10.3390/ph15070881
6. Pradeep M, Balakrishnan N, Arvind TRP. Prevalence of usage of various removable appliances among undergraduate dental students in a private dental college. J Adv Pharm Technol Res. 2022 Dec;13(Suppl 2):S559–62.
7. Bollareddy SR, Krishna V, Roy G, Dasari D, Dhar A, Venuganti VVK. Transfersome Hydrogel Containing 5-Fluorouracil and Etodolac Combination for Synergistic Oral Cancer Treatment. AAPS PharmSciTech. 2022 Feb 7;23(2):70.
8. Sathiyamoorthy S, Gheena S, Jain RK. Prevalence of oral mucocele among outpatients at saveetha dental hospital, india. Bioinformation. 2020 Dec 31;16(12):1013–8.
9. Rangel L. Cancer Treatment: Conventional and Innovative Approaches. BoD – Books on Demand; 2013. 632 p.
10. Wu S, Wang J, Fu Z, Familiari G, Relucenti M, Aschner M, et al. Matairesinol Nanoparticles Restore Chemosensitivity and Suppress Colorectal Cancer Progression in Preclinical Models: Role of Lipid Metabolism Reprogramming. Nano Lett. 2023 Mar 8;23(5):1970–80.
11. Dana P, Thumrongsiri N, Tanyapanyachon P, Chonniyom W, Punnakitikashem P, Saengkrit N. Resveratrol Loaded Liposomes Disrupt Cancer Associated Fibroblast Communications within the Tumor Microenvironment to Inhibit Colorectal Cancer Aggressiveness. Nanomaterials (Basel) [Internet]. 2022 Dec 25;13(1). Available from: http://dx.doi.org/10.3390/nano13010107
12. Smith T, Affram K, Nottingham EL, Han B, Amissah F, Krishnan S, et al. Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer. Sci Rep. 2020 Oct 12;10(1):16989.
13. Scavo MP, Cutrignelli A, Depalo N, Fanizza E, Laquintana V, Gasparini G, et al. Effectiveness of a Controlled 5-FU Delivery Based on FZD10 Antibody-Conjugated Liposomes in Colorectal Cancer In vitro Models. Pharmaceutics [Internet]. 2020 Jul 10;12(7). Available from: http://dx.doi.org/10.3390/pharmaceutics12070650
14. Sivakumar P, Gurunathan D. Behavior of Children toward Various Dental Procedures. Int J Clin Pediatr Dent. 2019 Sep-Oct;12(5):379–84.
15. Marverti G, Gozzi G, Maretti E, Lauriola A, Severi L, Sacchetti F, et al. A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells. Int J Mol Sci [Internet]. 2020 Jun 23;21(12). Available from: http://dx.doi.org/10.3390/ijms21124452
16. Kumar CSS. Nanomaterials for Cancer Therapy. Wiley-VCH; 2006. 448 p.
17. Ndemazie NB, Bulusu R, Zhu XY, Frimpong EK, Inkoom A, Okoro J, et al. Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. Int J Mol Sci [Internet]. 2023 Feb 21;24(5). Available from: http://dx.doi.org/10.3390/ijms24054288
18. Ulker D, Ozyurt R, Erkasap N, Butun V. Magnetic Targeting of 5-Fluorouracil-Loaded Liposome-Nanogels for In Vivo Breast Cancer Therapy and the Cytotoxic Effects on Liver and Kidney. AAPS PharmSciTech. 2022 Oct 31;23(8):289.
19. Woodle MC, Storm G. Long Circulating Liposomes: Old Drugs, New Therapeutics. Springer Science & Business Media; 2013. 301 p.
20. Bae YH, Mrsny RJ, Park K. Cancer Targeted Drug Delivery: An Elusive Dream. Springer Science & Business Media; 2013. 720 p.